Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Melanoma

Treatments: Other: Non-Interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT03438279

CA209-437

Details and patient eligibility

About

This study will review published trial literature and documents for Overall Survival (OS) to evaluate the association between the hazard of death and each baseline variable.

Enrollment: 600 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of melanoma

Exclusion criteria

• Age less than 18 years old

Trial design

600 participants in 1 patient group

First-Line Ipilimumab

Description:

patients who received ipilimumab as their first-line treatment

Treatment:

Other: Non-Interventional